Friday, Nov 20, 2026 The claims desk. Receipts included. POWERED BY LENZ ↗
IsThis

SURMOUNT-1 tested three once-weekly subcutaneous tirzepatide target doses against placebo over 72 weeks.

The Claim

In the Phase 3 SURMOUNT-1 trial, participants received once-weekly subcutaneous tirzepatide at doses of 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks.

The Short Version

The claim accurately describes the treatment arms and primary duration of SURMOUNT-1. The primary NEJM report, study protocol and trial registry confirm that this phase 3 trial assigned participants to once-weekly subcutaneous tirzepatide at target doses of 5 mg, 10 mg or 15 mg, or placebo, over 72 weeks.

Caveats

  • The listed doses were assigned target doses; treatment started at 2.5 mg and increased during a dose-escalation period of up to 20 weeks included within the 72 weeks.
  • Participants with prediabetes had a treatment extension to 176 weeks; the claim describes the primary 72-week period.
  • The protocol and registry describe the same Lilly-sponsored trial and are not independent replications of its findings.

The Receipts

  1. Tirzepatide Once Weekly for the Treatment of Obesity | New England Journal of Medicine

    nejm.org

  2. Tirzepatide highly effective for weight loss | Nature Reviews Endocrinology

    nature.com

  3. Protocol I8F-MC-GPHK(b)

    cdn.clinicaltrials.gov

  4. Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial - PubMed

    pubmed.ncbi.nlm.nih.gov

  5. Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials

    pubmed.ncbi.nlm.nih.gov

  6. Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis - PubMed

    pubmed.ncbi.nlm.nih.gov

  7. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - PubMed

    pubmed.ncbi.nlm.nih.gov

  8. Tirzepatide Yields Substantial Weight Loss in Patients with or Without Diabetes | NEJM Clinician

    clinician.nejm.org

  9. Tirzepatide for Obesity Treatment and Diabetes Prevention

    nejm.org

  10. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials - PubMed

    pubmed.ncbi.nlm.nih.gov

+ 19 more sources — see the full list on Lenz

Filed Under

SURMOUNT-1Tirzepatide

More Fact Checks